PC抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela cells, human liver cancer tissue, Primary antibody: P07532(PC Antibody) at dilution 1/100, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

**Background of PC Antibodies**

Phosphorylcholine (PC) antibodies are a subset of natural antibodies primarily of the IgM class, recognized for their role in innate immunity. These antibodies target phosphorylcholine, a molecular epitope found on microbial pathogens (e.g., *Streptococcus pneumoniae*) and oxidized low-density lipoproteins (oxLDL) in atherosclerotic plaques. First identified in the 1970s, PC antibodies are part of the body's first-line defense, bridging innate and adaptive immune responses.

Structurally, PC antibodies bind to PC moieties via conserved antigen-binding regions, enabling broad reactivity. Their production is partly T-cell-independent, arising from B1 B-cells in response to microbial exposure or endogenous danger signals. Functionally, they neutralize pathogens, promote phagocytosis, and modulate inflammation by interacting with C-reactive protein (CRP) or scavenger receptors.

Clinically, low levels of PC antibodies correlate with increased cardiovascular risk, as they help clear oxLDL and apoptotic cells, reducing plaque inflammation. Conversely, altered PC antibody responses are implicated in autoimmune diseases like lupus and rheumatoid arthritis, where their deficiency may exacerbate tissue damage. Recent studies explore their therapeutic potential, including anti-inflammatory agents or biomarkers for disease monitoring. Research continues to unravel their precise mechanisms and applications in immunology and translational medicine.

(Word count: 199)